Necitumumab (Portrazza)
On February 8th, 2016
On November 24, 2015, the U.S. Food and Drug Administration granted approval to necitumumab (PORTRAZZA, Eli Lilly and Company) in combination with gemcitabine and cisplatin for first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). Necitumumab is not indicated for treatment of non-squamous NSCLC.
Full prescribing information is available: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf
On November 24, 2015, the U.S. Food and Drug Administration granted approval to necitumumab (PORTRAZZA, Eli Lilly and Company) in combination with gemcitabine and cisplatin for first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). Necitumumab is not indicated for treatment of non-squamous NSCLC.
Full prescribing information is available: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf
No comments have been posted yet.